Background
==========

Cardiac failure in septic shock usually originates from hypovolaemia, impaired global contractility or right ventricular failure (RVF). Acute RVF due to endotoxin-mediated pulmonary hypertension results in global hypoperfusion. However, the treatment of pulmonary vascular resistance (PVR) in septic patients remains a black box.

Methods
=======

After ethical approval, septic shock was induced in 32 pigs ( 25 ± 3 kg) by continuous infusion of endotoxin (Escherichia coli serotype 0111:B4). The animals received a protocol-based treatment with fluids and vasopressors according to the surviving sepsis campaign guidelines. Then, they were randomized to either inhaled (i.h.) (240μg kg^-1^) or intravenous (i.v.) (24μg kg^-1^) treatment with BAY 41-8543 or controls. Heart rate (HR (bpm)), mean arterial pressure (MAP (mmHg)), mean pulmonary artery pressure (MPAP (mmHg)), cardiac output (CO (l min^-1^)) and PVR (dyn sec cm^-5^) were assessed every 15 minutes for 1 h after starting the treatment. Following a wash out period of 1 h, the animals were once more randomized to double dose (D2) i.h. or i.v. respectively or to simultaneous administration of Bay 41-8543 at a single dose together with NO (i.h.) at 20 ppm. Hemodynamic measurements were taken for another hour. Data are expressed as mean ± SD at shock and 30 minutes after treatment. Differences between groups were analyzed using a linear mixed-effects model.

Results
=======

Both during i.h. and i.v. application of BAY 41-8543, a significant decrease in PVR and an increase in CO was observed. Additive inhaled NO decreased PVR more than doubling the dose of BAY 41-8543 (Table [1](#T1){ref-type="table"}).

  ---------------------------------------------------------------------------------------------------------------------------
             shock\         i.h.\          i.v.\          con\     i.h. D2\   i.h. no\      i.v. D2\   i.v. no\    con no\
             ***(n=32)***   ***(n=12)***   ***(n=14)***   (n=6)    (n=6)      ***(n=5)***   (n=5)      (n=5)       (n=5)
  ---------- -------------- -------------- -------------- -------- ---------- ------------- ---------- ----------- ----------
  **HR**     127\           150\           163\*\*\       123\     140\       146\          171\       148\        113\
             (34)           (21)           (28)           (34)     (35)       (19)          (29)       (29)        (34)

  **MAP**    58\            71\            68\            73\      75\        69\           68\        73\         73\
             (7)            (7)            (6)            (8)      (6)        (9)           (14)       (10)        (8)

  **MPAP**   38\            40\            37\            44\      42\        42\           40\        37\*\*\     39\*\*\
             (7)            (7)            (8)            (6)      (10)       (9)           (16)       (9)         (9)

  **PVR**    1246\          491\*\*\       469\*\*\       972\     691\*\*\   573\*\*\      849\*\     460\*\*\    887\*\*\
             (401)          (106)          (198)          (325)    (322)      (245)         (815)      (103)       (296)

  **CO**     2.02\          4.65\*\*\      5.04\*\*\      2.93\    3.73\      4.16\*\       4.3\*\*\   4.06\*\*\   2.46\
             (0.51)         (0.76)         (1.43)         (0.89)   (1.71)     (1.44)        (2.85)     (0.78)      (0.67)
  ---------------------------------------------------------------------------------------------------------------------------

\* p\<0.05   \*\*p\<0.01   vs. control group (con)

Conclusion
==========

The stimulator of the soluble guanylate cyclase BAY 41-8543 offers a treatment option for pulmonary hypertension in septic shock. Both inhalative and intravenous administration of BAY 41-8543 reduces PVR and increase CO. Further, there seems to be an additive effect of inhaled NO.
